Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Font Size

New Rheumatoid Arthritis Drug in the Works

Researchers Report Relief From RA Symptoms for Patients Taking Masitinib
WebMD Health News
Reviewed by Louise Chang, MD

June 29, 2009 -- An experimental drug called masitinib may ease rheumatoid arthritis symptoms in people who aren't helped by other drugs, a new study shows.

That study, published online in Arthritis Research & Therapy, included 40 adults in France who had rheumatoid arthritis (RA) that didn't respond to other RA drugs.

For 12 weeks, the patients took masitinab tablets twice daily at various doses. Patients whose RA eased during that time could opt to continue masitinib treatment.

Masitinib targets immune system cells called mast cells. The goal is to interrupt a chain reaction of inflammatory chemicals that may contribute to rheumatoid arthritis. Masitinib is also being studied as a cancer drug.

Roughly half of the patients had their RA symptoms ease during the study.

Almost all of the patients -- 95% -- reported some adverse event during the study. Most adverse events were mild to moderate and temporary, such as rashes, swelling, nausea, and diarrhea.

Four patients had severe adverse events (skin rash, pneumonia, fluid buildup near the lungs, and RA flare-up), and 37% of all patients quit the study because of adverse events.

Adverse events were most common during the first month of masitinib treatment, and overall, the researchers considered masitinib to have a "favorable" profile for longer-term treatment. They're still working on finding the optimal dose of the drug that will be effective but limit side effects.

The study was sponsored by AB Science, the drug company that's developing masitinib. Several of the researchers are AB Science employees.

Today on WebMD

rubbing hands
Avoid these 6 common mistakes.
mature couple exercising
Decrease pain, increase energy.
mature woman threading needle
How much do you know?
Swelling, fatigue, pain, and more.
Lucille Ball
Hand bones X-ray
prescription pills
Woman massaging her neck
woman roasting vegetables in oven
Woman rubbing shoulder
Working out with light weights